Gilead's sofosbuvir recommended for compassionate use in Europe
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's advisory committee, the CHMP, has recommended that Gilead Sciences' hepatitis C virus (HCV) infection drug sofosbuvir be used in a compassionate-use program in patients who have had, or who need, a liver transplant.